STRATEGIC INSIGHTS INTO THE NON-SURGICAL TREATMENT OF VASCULAR MALFORMATIONS: THE PIVOTAL ROLE OF BLEOMYCIN ELECTROSCLEROTHERAPY (BEST)
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5320Keywords:
Vascular Malformations, BEST, Bleomycin, Electrosclerotherapy, Minimally Invasive Treatment, Interventional RadiologyAbstract
Objective: This study evaluates the efficacy, safety, and clinical outcomes of non-surgical management of vascular malformations, with a specific focus on the emerging role of Bleomycin Electrosclerotherapy (BEST).
Methods: A comprehensive analysis of publicly available scientific literature (2011-2026) was performed using major medical databases. The study emphasizes the synergistic mechanism of reversible electroporation combined with bleomycin and reviews clinical outcomes across various low-flow vascular subsets.
Results: Bleomycin Electrosclerotherapy (BEST) demonstrates superior localized control compared to conventional sclerotherapy. By inducing a "vascular lock" effect and increasing cell membrane permeability, BEST enhances bleomycin’s intracellular concentration by several orders of magnitude. Clinical data indicate significant lesion volume reduction (exceeding 80–90% in targeted cohorts) with a reduced number of treatment sessions. Furthermore, the localized nature of the procedure minimizes systemic toxicity and preserves surrounding healthy tissue, leading to excellent aesthetic and functional outcomes, particularly in anatomically complex regions such as the head and neck.
Conclusion: Non-surgical interventions, spearheaded by BEST, represent a paradigm shift in the treatment of vascular malformations. This modality offers a highly effective, tissue-sparing alternative to radical surgery and traditional sclerotherapy, establishing itself as a potential gold standard for the management of refractory and sensitive vascular anomalies.
References
ISSVA Board. (2018). ISSVA classification for vascular anomalies. International Society for the Study of Vascular Anomalies. https://www.issva.org/classification
Bertino, G., Sersa, G., De Terlizzi, F., et al. (2016). European standard operating procedures for electrochemotherapy and bleomycin electrosclerotherapy (BEST). European Journal of Surgical Oncology, 42(12), 1827–1842. https://doi.org/10.1016/j.ejso.2016.10.011
Muir, T., Kulkarni, R., Christie Brown, J., & Harrington, K. J. (2014). Bleomycin electrosclerotherapy (BEST) for the treatment of vascular malformations. British Journal of Oral and Maxillofacial Surgery, 52(8), e72. https://doi.org/10.1016/j.bjoms.2014.07.255
Plasencia, J., Muir, T., et al. (2020). Bleomycin electrosclerotherapy: A novel and effective treatment for vascular malformations. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 8(2), 275–282. https://doi.org/10.1016/j.jvsv.2019.09.004
Sersa, G., et al. (2015). BEST: An emerging treatment for vascular malformations. Radiology and Oncology, 49(4), 313–322. https://doi.org/10.1515/raon-2015-0038
Schultz, R., Sotiropoulos, G., & Richter, G. T. (2018). Low-dose bleomycin sclerotherapy in the management of lymphatic malformations: Long-term pulmonary safety. Pediatric Radiology, 48(11), 1560–1568. https://doi.org/10.1007/s00247-018-4220-z
Cahill, A. M., & Nijs, E. L. (2011). The role of interventional radiology in the management of vascular malformations. AJR. American Journal of Roentgenology, 197(5), W813–W822. https://doi.org/10.2214/AJR.10.4899
Richter, G. T., & Friedman, A. B. (2012). Hemangiomas and vascular malformations: Current theory and management. Nature Reviews Neurology, 8(3), 185–196. https://doi.org/10.1038/nrneurol.2012.3
Wierzbicka, M., Bartochowska, A., et al. (2014). Electroporation in the treatment of vascular malformations in the head and neck. Otolaryngologia Polska, 68(4), 175–180. https://doi.org/10.1016/j.otpol.2014.02.001
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Aleksandra Arczewska, Julia Kacperczyk, Julia Bezak, Mateusz Winkler, Michał Zaborowski, Klaudia Purgał-Zaborowska, Klaudia Michałowska, Oliwier Kolanowski, Olga Turzańska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
